Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review

IF 6.1 1区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Analysis Pub Date : 2023-12-01 DOI:10.1016/j.jpha.2023.08.009

Changhong Nie, Ibrahim Shaw, Chuanpin Chen

{"title":"Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review","authors":"Changhong Nie, Ibrahim Shaw, Chuanpin Chen","doi":"10.1016/j.jpha.2023.08.009","DOIUrl":null,"url":null,"abstract":"<div><p>With the continuous discovery and research of predictive cancer-related biomarkers, liquid biopsy shows great potential in cancer diagnosis. Surface-enhanced Raman scattering (SERS) and microfluidic technology have received much attention among the various cancer biomarker detection methods. The former has ultrahigh detection sensitivity and can provide a unique fingerprint. In contrast, the latter has the characteristics of miniaturization and integration, which can realize accurate control of the detection samples and high-throughput detection through design. Both have the potential for point-of-care testing (POCT), and their combination (lab-on-a-chip SERS (LoC-SERS)) shows good compatibility. In this paper, the basic situation of circulating proteins, circulating tumor cells, exosomes, circulating tumor DNA (ctDNA), and microRNA (miRNA) in the diagnosis of various cancers is reviewed, and the detection research of these biomarkers by the LoC-SERS platform in recent years is described in detail. At the same time, the challenges and future development of the platform are discussed at the end of the review. Summarizing the current technology is expected to provide a reference for scholars engaged in related work and interested in this field.</p></div>","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"13 12","pages":"Pages 1429-1451"},"PeriodicalIF":6.1000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095177923002009/pdfft?md5=a1469761fcb4a6733e5690d5b6055730&pid=1-s2.0-S2095177923002009-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2095177923002009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

With the continuous discovery and research of predictive cancer-related biomarkers, liquid biopsy shows great potential in cancer diagnosis. Surface-enhanced Raman scattering (SERS) and microfluidic technology have received much attention among the various cancer biomarker detection methods. The former has ultrahigh detection sensitivity and can provide a unique fingerprint. In contrast, the latter has the characteristics of miniaturization and integration, which can realize accurate control of the detection samples and high-throughput detection through design. Both have the potential for point-of-care testing (POCT), and their combination (lab-on-a-chip SERS (LoC-SERS)) shows good compatibility. In this paper, the basic situation of circulating proteins, circulating tumor cells, exosomes, circulating tumor DNA (ctDNA), and microRNA (miRNA) in the diagnosis of various cancers is reviewed, and the detection research of these biomarkers by the LoC-SERS platform in recent years is described in detail. At the same time, the challenges and future development of the platform are discussed at the end of the review. Summarizing the current technology is expected to provide a reference for scholars engaged in related work and interested in this field.

Abstract Image

查看原文本刊更多论文

基于表面增强拉曼散射的微流控技术在癌症生物标志物检测中的应用综述

随着预测性癌症相关生物标记物的不断发现和研究，液体活检在癌症诊断中显示出巨大的潜力。在各种癌症生物标记物检测方法中，表面增强拉曼散射（SERS）和微流控技术备受关注。前者具有超高的检测灵敏度，并能提供独特的指纹。而后者则具有微型化和集成化的特点，可以通过设计实现对检测样品的精确控制和高通量检测。二者都有可能用于床旁检测（POCT），它们的组合（片上实验室 SERS（LoC-SERS））显示出良好的兼容性。本文回顾了循环蛋白、循环肿瘤细胞、外泌体、循环肿瘤 DNA（ctDNA）和微RNA（miRNA）在各种癌症诊断中的基本情况，并详细介绍了近年来 LoC-SERS 平台对这些生物标记物的检测研究。同时，在综述的最后讨论了该平台面临的挑战和未来的发展。通过对现有技术的总结，希望能为从事相关工作和对该领域感兴趣的学者提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Analysis Chemistry-Electrochemistry

CiteScore

16.20

自引率

2.30%

发文量

674

审稿时长

22 weeks

期刊介绍： The Journal of Pharmaceutical Analysis (JPA), established in 2011, serves as the official publication of Xi'an Jiaotong University. JPA is a monthly, peer-reviewed, open-access journal dedicated to disseminating noteworthy original research articles, review papers, short communications, news, research highlights, and editorials in the realm of Pharmacy Analysis. Encompassing a wide spectrum of topics, including Pharmaceutical Analysis, Analytical Techniques and Methods, Pharmacology, Metabolism, Drug Delivery, Cellular Imaging & Analysis, Natural Products, and Biosensing, JPA provides a comprehensive platform for scholarly discourse and innovation in the field.